Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 22, 2024 Category: Cancer & Oncology Authors: Sarah K. Jacques, Janet McKeown, Piyush Grover, Douglas B. Johnson, Anne Zaremba, Florentia Dimitriou, Roi Weiser, Mohamad Farid, Kenjiro Namikawa, Ryan J. Sullivan, Piotr Rutkowski, Celeste Lebbe, Omid Hamid, Jonathan S. Zager, Olivier Michielin, Bart Ne Tags: Original Research Source Type: research
Early Morning Immune Checkpoint Blockade and Overall Survival of Patients with Metastatic Cancer: an In-depth Chronotherapeutic Study
Recent retrospective studies suggest potential large patient ’s benefit through proper timing of immune checkpoint blockers (ICB). The association between ICB treatment timing and patient survival, neoplastic response and toxicities was investigated, together with interactions with performance status (PS) and sex. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 22, 2024 Category: Cancer & Oncology Authors: Simona Catozzi, Souad Assaad, Lidia Delrieu, Bertrand Favier, Elise Dumas, Anne-Sophie Hamy, Aur élien Latouche, Hugo Crochet, Jean-Yves Blay, Jimmy Mullaert, Annabelle Ballesta, Pierre Heudel Tags: Original Research Source Type: research
Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer
The introduction of national guidelines should eliminate previously observed associations between socioeconomic status (SES) and colorectal cancer treatment. The aim of the study was to investigate whether inequalities remain. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 22, 2024 Category: Cancer & Oncology Authors: Erik Osterman, Elisavet Syriopoulou, Anna Martling, Therese M-L Andersson, Caroline Nordenvall Tags: Original Research Source Type: research
Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy
To assess survival outcomes of stage IA3 endometrial cancer and the association of adjuvant therapy and survival. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 21, 2024 Category: Cancer & Oncology Authors: Koji Matsuo, Ling Chen, Monica K. Neuman, Maximilian Klar, Lynda D. Roman, Jason D. Wright Tags: Original Research Source Type: research
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
Neoadjuvant chemotherapy (NACT) with TPF (docetaxel, cisplatin, and 5FU) is one of the treatment options in very locally advanced oral cancer with a survival advantage over PF (cisplatin and 5FU). TP (docetaxel and cisplatin) has shown promising results with a lower rate of adverse events but has never been compared to TPF. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Vanita Noronha, Vijay Patil, Pankaj Chaturvedi, Vijayalakshmi Mathrudev, Nandini Menon, Atanu Bhattacharjee, Ajay Singh, Zoya Peelay, Shatabdi Chakraborty, Monica Jadhav, Mitali Alone, Priyanka Bhagyavant, Manali Kolkur, Sujay Srinivas, Sudeep Das, Somnat Tags: Original Research Source Type: research
Efficacy and Safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
Anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. BRAFV600-mutated (BRAFmut) melanoma patients who recur with isolated disease following adjuvant therapy may be suitable for ‘second adjuvant' treatment after local therapy. We sought to examine the efficacy and safety of ‘second adjuvant’ BRAF/MEKi. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Amelia M Taylor, Janet McKeown, Florentia Dimitriou, Sarah K Jacques, Lisa Zimmer, Clara Allayous, Hui-Ling Yeoh, Andrew Haydon, Julia M Ressler, Claire Galea, Rachel Woodford, Katharina Kahler, Axel Hauschild, Lucia Festino, Christoph Hoeller, Julia K Sc Tags: Original Research Source Type: research
Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios.
The remarkable outcomes achieved with neoadjuvant checkpoint inhibitors for patients diagnosed with MSI colorectal cancer hold the potential to revolutionize the treatment landscape in this context. Specifically, the combination of nivolumab plus ipilimumab in colon cancer and dostarlimab in rectal cancer has led to an unprecedented rate of complete pathological and clinical responses. Notably, these responses have been further substantiated by the absence of relapses, with a 0% relapse rate observed during the first year of follow-up. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Alessandro Pastorino, Fabio Catalano, John R. Zalcberg, Alberto Sobrero Tags: Current Perspective Source Type: research
Revolutionizing Anti-HER2 Therapies for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Current Advancements and Future Perspectives
Biliary tract cancers (BTCs) encompass a heterogeneous group of rare tumors, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer (GBC) and ampullary cancer (AC). The present first-line palliative treatment regimen comprises gemcitabine and cisplatin in combination with immunotherapy based on two randomized controlled studies. Despite the thorough investigation of these palliative treatments, long-term survival remains low.Moving beyond conventional chemotherapies and immunotherapies, the realm of precision medicine has demonstrated remarkable efficacy in malignancies...
Source: European Journal of Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Britte HEA ten Haaft, Manuel Pedregal, Javier Prato, Heinz-Josef Kl ümpen, Victor Moreno, Angela Lamarca Tags: Review Source Type: research
Combined immunotherapy in melanoma patients with brain metastases: a multicenter international study
We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO outside clinical trials. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 18, 2024 Category: Cancer & Oncology Authors: Mario Mandal à, Paul Lorigan, Maria Chiara Sergi, Naima Benannoune, Patricio Serra, Maria Grazia Vitale, Diana Giannarelli, Ana Maria Arance, Eva Munoz Couselo, Bart Neyns, Marco Tucci, Michele Guida, Francesco Spagnolo, Ernesto Rossi, Marcella Occelli, Tags: Original Research Source Type: research
Association of antibiotic treatment with survival outcomes in treatment-na ïve melanoma patients receiving immune checkpoint blockade
The interaction of gut microbiome and immune system is being studied with increasing interest. Disturbing factors, such as antibiotics may impact the immune system via gut and interfere with tumor response to immune checkpoint blockade (ICB). (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 18, 2024 Category: Cancer & Oncology Authors: Eleftheria Chorti, Bernd Kowall, Jessica C Hassel, Bastian Schilling, Michael Sachse, Ralf Gutzmer, Carmen Loquai, Katharina C K ähler, Anika Hüsing, Catharina Gilde, Carl M. Thielmann, Anne Zaremba-Montenari, Jan-Malte Placke, Emmanouil Gratsias, Anna Tags: Original Research Source Type: research
Advancing Data Collection and Analysis: 2023 Revised European Network of Cancer Registries Recommendations for Standard Dataset
Dear Editor-in-chief, (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 17, 2024 Category: Cancer & Oncology Authors: Irmina Maria Michalek, Carmen Martos, Florentino Luciano Caetano dos Santos, Francesco Giusti, Henna Degerlund, Luciana Neamtiu, Lukasz Taraszkiewicz, Liesbet Van Eycken, Otto Visser Tags: Letter to the Editor Source Type: research
Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium
Results from MAITA confirm that DBT is superior to DM for the detection of cancers, with a possible increase in recall rate. DBT performance in screening should be assessed locally while waiting for long-term follow-up results on the impact of advanced cancer incidence. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 16, 2024 Category: Cancer & Oncology Authors: Paolo Giorgi Rossi, Pamela Mancuso, Pierpaolo Pattacini, Cinzia Campari, Andrea Nitrosi, Valentina Iotti, Antonio Ponti, Alfonso Frigerio, Loredana Correale, Emilia Riggi, Livia Giordano, Nereo Segnan, Giovanni Di Leo, Veronica Magni, Francesco Sardanelli Tags: Clinical Trial Source Type: research
Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d ′Étude des Tumeurs Uro-Génitales) study
Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: F. Carneiro, A. Vinceneux, M. Larroquette, M. Rony, L. Carril, B. Laguerre, I. Blazevic, P. Bartelemy, D. Teyssonneau, M. Goujon, C. Linassier, A. Thiery-Vuillemin, G. Roubaud, L. Mourey, L. Albiges, G. Gravis, M. Gross-Goupil, M. Cancel Tags: Original research Source Type: research
Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
In monarchE, abemaciclib demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile at 42-months median follow-up. With no expected disease-related symptoms, therapies in the adjuvant setting should preserve quality of life (QoL). With all patients off abemaciclib, we report updated patient-reported outcomes (PROs) for the full 2-year treatment period and follow-up. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Sara M. Tolaney, Valentina Guarneri, Jae Hong Seo, Josefina Cruz, Miguel Henriques Abreu, Masato Takahashi, Carlos Barrios, Kristi McIntyre, Ran Wei, Maria Munoz, Belen San Antonio, Astra M. Liepa, Miguel Martin, Stephen R.D. Johnston, Pirkko-Liisa Kellok Tags: Original Research Source Type: research
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (MET Δ14ex) remains controversial. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Miriam Blasi, Jonas Kuon, Heike L üders, Daniel Misch, Diego Kauffmann-Guerrero, Moritz Hilbrandt, Daniel Kazdal, Roger-Fei Falkenstern-Ge, Björn Hackanson, Sebastian Dintner, Martin Faehling, Martina Kirchner, Anna-Lena Volckmar, Hans-Georg Kopp, Micha Tags: Original Research Source Type: research
